Policy Evaluation for Regulating Toxic Traditional Chinese Medicines in Taiwan
Risk Management and Healthcare Policy · 2026-02 · Volume 19 · 1-9
DOI: 10.2147/rmhp.s577383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Risk Management and Healthcare Policy, 2026-02. Verfasst von Yi-Shan Lan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chinese Medicine, Puzi Hospital Ministry of Health and Welfare, Puzi, Taiwan. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
In recent years, growing reports of poisoning and adverse reactions linked to the misuse of traditional Chinese medicine (TCM) have raised increasing concerns about its safety. This article begins with the case of aristolochic acid nephropathy and draws on international regulatory practices to evaluate Taiwan's legal and policy framework governing toxic TCMs. The analysis reveals systemic deficiencies in the Taiwan Herbal Pharmacopoeia and related regulations, particularly in the classification of toxic substances, Paozhi (processing methods), and dosage safety standards. The article argues that the regulation of toxic TCMs should be grounded in scientific methodology and toxicological principles, incorporating risk assessment to establish rational toxicity classifications, standardized processing protocols, and usage restrictions, thereby enabling clinical practice to achieve the goal of high efficacy with low toxicity. It further advocates for the implementation of adverse event reporting mechanisms to safeguard public health. In recent years, researchers and regulatory bodies have increasingly focused on the safety of traditional Chinese medicine (TCM), responding to recurrent reports of poisoning and adverse reactions caused by improper usage. To improve the safe administration of TCM, this study conducts a comprehensive evaluation of existing regulatory frameworks. We investigate the governance of toxic Chinese medicinal substances in Taiwan by examining documented poisoning incidents and analyzing current regulatory policies in comparison with international standards and practices. Our analysis identifies systemic deficiencies in the Taiwan Pharmacopoeia and related regulations, particularly in toxicity classification, processing methods (Paozhi), dosage safety, and adverse reaction reporting mechanisms. We advocate for a science-based regulatory approach that applies toxicological principles and risk assessment methodologies. We recommend establishing rational usage restrictions and standardized toxicity classifications to ensure the safe and effective use of toxic Chinese herbs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chinese Medicine, Puzi Hospital Ministry of Health and Welfare, Puzi, Taiwan.
- School of Chinese Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Chinese Medicine, Taipei Municipal Gan-Dau Hospital (Managed by Taipei Veterans General Hospital), Taipei, Taiwan.
- Department of Chinese Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
- School of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Law, College of Social Sciences, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Yi-Shan Lan, Po-Hsun Chen, Yu-Pei Chen
Zitieren
APA
Lan, Y. S., Chen, P. H., & Chen, Y. P. (2026). Policy Evaluation for Regulating Toxic Traditional Chinese Medicines in Taiwan. Risk Management and Healthcare Policy, Volume 19, 1-9. https://doi.org/10.2147/rmhp.s577383
Vancouver
Lan YS, Chen PH, Chen YP. Policy Evaluation for Regulating Toxic Traditional Chinese Medicines in Taiwan. Risk Management and Healthcare Policy. 2026;Volume 19:1-9. doi:10.2147/rmhp.s577383
BibTeX
@article{Lan2026,
author = {Lan, Yi-Shan and Chen, Po-Hsun and Chen, Yu-Pei},
title = {Policy Evaluation for Regulating Toxic Traditional Chinese Medicines in Taiwan},
journal = {Risk Management and Healthcare Policy},
year = {2026},
volume = {Volume 19},
pages = {1--9},
doi = {10.2147/rmhp.s577383}
}
EUVIMED